Granted Patent
B2
US 12,595,309 · App. 18/942,051 · Granted Apr 7, 2026
Compositions and methods for treatment of thyroid eye disease
Inventors:
Vahe Bedian (Waltham, MA); Peter Harwin (Dorado, PR); Tomas Kiselak (Dorado, PR); Angela She (Waltham, MA); Jonathan Violin (Waltham, MA); Yang Zhao (Waltham, MA)
Assignee:
Viridian Therapeutics, Inc.
C07K16/2863A61K9/0019A61P27/02A61K2039/505A61K2039/545C07K2317/24C07K2317/51C07K2317/515C07K2317/56C07K2317/565C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS), by inhibiting the activity of IGF-1R with such antibodies and compositions.
Claims (24)
1 . A method of treating thyroid eye disease (TED) in a human subject having TED and in need thereof, the method comprising administering an anti-IGF-1R antibody to the human subject,
wherein the anti-IGF-1R antibody comprises a light chain comprising a LCDR1 having an amino acid sequence of SEQ ID NO: 53, a LCDR2 having an amino acid sequence of SEQ ID NO: 54, and a LCDR3 having an amino acid sequence of SEQ ID NO: 55, and a heavy chain comprising a HCDR1 having an amino acid sequence of SEQ ID NO: 56, a HCDR2 having an amino acid sequence of SEQ ID NO: 57, and a HCDR3 having an amino acid sequence of SEQ ID NO: 58.
2 . The method of claim 1 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13.
3 . The method of claim 1 , wherein the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
4 . The method of claim 2 , wherein the light chain has an amino acid sequence of SEQ ID NO: 93.
5 . The method of claim 3 , wherein the heavy chain has an amino acid sequence of SEQ ID NO: 92.
6 . The method of claim 1 , wherein the anti-IGF-1R antibody is administered intravenously.
7 . The method of claim 1 , wherein treating TED further comprises reducing proptosis in an eye in the human subject after administration of the anti-IGF-1R antibody.
8 . The method of claim 7 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13.
9 . The method of claim 7 , wherein the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
10 . The method of claim 7 , wherein proptosis is reduced by at least 2 mm as measured by an exophthalmometer.
11 . The method of claim 10 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13.
12 . The method of claim 10 , wherein the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
13 . The method of claim 1 , wherein treating TED further comprises reducing the severity of diplopia in the human subject.
14 . The method of claim 13 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13.
15 . The method of claim 13 , wherein the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
16 . The method of claim 1 , wherein treating TED comprises reducing a Clinical Activity Score (CAS) of the human subject following administration of the anti-IGF-1R antibody.
17 . The method of claim 16 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13.
18 . The method of claim 16 , wherein the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
19 . The method of claim 1 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13 and the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
20 . The method of claim 7 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13 and the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
21 . The method of claim 10 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13 and the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
22 . The method of claim 13 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13 and the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
23 . The method of claim 16 , wherein the light chain comprises a variable region having an amino acid sequence of SEQ ID NO: 13 and the heavy chain comprises a variable region having an amino acid sequence of SEQ ID NO: 14.
Assignments (2)
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Oct 20, 2025
From: VIRIDIAN THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 073121/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 3, 2024
From: BEDIAN, VAHE; HARWIN, PETER; KISELAK, TOMAS; SHE, ANGELA; VIOLIN, JONATHAN; ZHAO, YANG
To: VIRIDIAN THERAPEUTICS, INC.
Reel/Frame 069466/0201 →
Continuity (8)
Provisional Application
63261742
· Sep 28, 2021
Provisional Application
63260130
· Aug 10, 2021
Provisional Application
63201978
· May 21, 2021
Provisional Application
63091839
· Oct 14, 2020
References Cited (339)
US 4439196A
· Higuchi
· 1984
[cited by applicant]
US 4447224A
· Decant et al.
· 1984
[cited by applicant]
US 4447233A
· Mayfield
· 1984
[cited by applicant]
US 4487603A
· Harris
· 1984
[cited by applicant]
US 4596556A
· Morrow et al.
· 1986
[cited by applicant]
US 4790824A
· Morrow et al.
· 1988
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4941880A
· Burns
· 1990
[cited by applicant]
US 4949778A
· Saito et al.
· 1990
[cited by applicant]
US 5064413A
· Mckinnon et al.
· 1991
[cited by applicant]
US 5260203A
· Ladner et al.
· 1993
[cited by applicant]
US 5312335A
· Mckinnon et al.
· 1994
[cited by applicant]
US 5383851A
· Mckinnon et al.
· 1995
[cited by applicant]
US 5399163A
· Peterson et al.
· 1995
[cited by applicant]
US 5475096A
· Gold et al.
· 1995
[cited by applicant]
US 5831012A
· Nilsson et al.
· 1998
[cited by applicant]
US 6004746A
· Brent et al.
· 1999
[cited by applicant]
US 6005079A
· Casterman et al.
· 1999
[cited by applicant]
US 6096002A
· Landau
· 2000
[cited by applicant]
US 6620135B1
· Weston et al.
· 2003
[cited by applicant]
US 6794144B1
· Saksela et al.
· 2004
[cited by applicant]
US 6818418B1
· Lipovsek et al.
· 2004
[cited by applicant]
US 6994982B1
· Watt et al.
· 2006
[cited by applicant]
US 7083784B2
· Dall et al.
· 2006
[cited by applicant]
US 7166697B1
· Galanis et al.
· 2007
[cited by applicant]
US 7186524B2
· Kolmar et al.
· 2007
[cited by applicant]
US 7250297B1
· Beste et al.
· 2007
[cited by applicant]
US 7417130B2
· Stumpp et al.
· 2008
[cited by applicant]
US 7572897B2
· Graus et al.
· 2009
[cited by applicant]
US 7670600B2
· Dall et al.
· 2010
[cited by applicant]
US 7803907B2
· Stemmer et al.
· 2010
[cited by applicant]
US 7838629B2
· Fiedler et al.
· 2010
[cited by applicant]
US 7998681B2
· Smith et al.
· 2011
[cited by applicant]
US 8137933B2
· Saha
· 2012
[cited by applicant]
US 8153121B2
· Smith et al.
· 2012
[cited by applicant]
US 8394925B2
· Chamberlain et al.
· 2013
[cited by applicant]
US 8951790B2
· Saha
· 2015
[cited by applicant]
US 9045536B2
· Merchant et al.
· 2015
[cited by applicant]
US 9982036B2
· Bossenmaier et al.
· 2018
[cited by applicant]
US 20040023334A1
· Prior
· 2004
[cited by applicant]
US 20040132094A1
· Etzerodt et al.
· 2004
[cited by applicant]
US 20040146938A1
· Nguyen et al.
· 2004
[cited by applicant]
US 20040157209A1
· Yilmaz et al.
· 2004
[cited by applicant]
US 20040202651A1
· Cohen et al.
· 2004
[cited by applicant]
US 20040209243A1
· Nixon et al.
· 2004
[cited by applicant]
US 20060286103A1
· Kolhe et al.
· 2006
[cited by applicant]
US 20070041972A1
· Rother et al.
· 2007
[cited by applicant]
US 20080014203A1
· Hansen et al.
· 2008
[cited by applicant]
US 20080112888A1
· Wang
· 2008
[cited by applicant]
US 20080226635A1
· Koll et al.
· 2008
[cited by applicant]
US 20090275126A1
· Graus et al.
· 2009
[cited by applicant]
US 20100104645A1
· Ali et al.
· 2010
[cited by applicant]
US 20100119446A1
· Grabulovski et al.
· 2010
[cited by applicant]
US 20100143340A1
· Kolhe et al.
· 2010
[cited by applicant]
US 20100260668A1
· Ghayur et al.
· 2010
[cited by applicant]
US 20110014117A1
· Wang et al.
· 2011
[cited by applicant]
US 20110014207A1
· Gualberto et al.
· 2011
[cited by applicant]
US 20110044980A1
· Ghayur et al.
· 2011
[cited by applicant]
US 20110229933A1
· Krishnan et al.
· 2011
[cited by applicant]
US 20110263827A1
· Ghayur et al.
· 2011
[cited by applicant]
US 20120014957A1
· Ghayur et al.
· 2012
[cited by applicant]
US 20120076778A1
· Koll et al.
· 2012
[cited by applicant]
US 20120100166A1
· Roschke et al.
· 2012
[cited by applicant]
US 20120201746A1
· Liu et al.
· 2012
[cited by applicant]
US 20120237507A1
· Bossenmaier et al.
· 2012
[cited by applicant]
US 20120263722A1
· Ghayur et al.
· 2012
[cited by applicant]
US 20130004416A1
· Wu et al.
· 2013
[cited by applicant]
US 20130195871A1
· Ghayur et al.
· 2013
[cited by applicant]
US 20130259868A1
· Roschke et al.
· 2013
[cited by applicant]
US 20140050729A1
· Yao
· 2014
[cited by applicant]
US 20140079665A1
· Goetsch et al.
· 2014
[cited by applicant]
US 20150017168A1
· Ghayur et al.
· 2015
[cited by applicant]
US 20150056191A1
· Sathyanarayanan et al.
· 2015
[cited by applicant]
US 20150168424A1
· Wang
· 2015
[cited by applicant]
US 20160060299A1
· Luesch
· 2016
[cited by applicant]
US 20160096894A1
· Cohen et al.
· 2016
[cited by applicant]
US 20160151487A1
· Hartmann et al.
· 2016
[cited by applicant]
US 20170218091A1
· Ambrosi
· 2017
[cited by applicant]
US 20180243432A1
· Poma et al.
· 2018
[cited by applicant]
US 20210253719A1
· Sherman et al.
· 2021
[cited by applicant]
US 20210284741A1
· Madden et al.
· 2021
[cited by applicant]
US 20220088231A1
· Burak et al.
· 2022
[cited by applicant]
US 20220235137A1
· Bedian et al.
· 2022
[cited by applicant]
US 20220267450A1
· Bedian et al.
· 2022
[cited by applicant]
US 20220267451A1
· Bedian et al.
· 2022
[cited by applicant]
US 20220275096A1
· Bedian
· 2022
[cited by examiner]
US 20230002495A1
· Bedian et al.
· 2023
[cited by applicant]
US 20230084477A1
· O'shaughnessy et al.
· 2023
[cited by applicant]
US 20230270851A1
· Korn et al.
· 2023
[cited by applicant]
US 20240043546A1
· Bedian
· 2024
[cited by examiner]
US 20240343814A1
· Bedian
· 2024
[cited by examiner]
US 20240352133A1
· Bedian
· 2024
[cited by examiner]
US 20240360227A1
· Bedian
· 2024
[cited by examiner]
US 20240368282A1
· Schlegel
· 2024
[cited by examiner]
US 20250099583A1
· Huyghe
· 2025
[cited by examiner]
CN 101229371A
· 2008
[cited by applicant]
CN 101292036A
· 2008
[cited by applicant]
CN 106456800A
· 2017
[cited by applicant]
CN 106546800A
· 2017
[cited by applicant]
CN 107406500A
· 2017
[cited by applicant]
CN 107708666A
· 2018
[cited by applicant]
CN 111315213A
· 2020
[cited by applicant]
CN 111744013A
· 2020
[cited by applicant]
CN 113402602A
· 2021
[cited by applicant]
EP 0404097A2
· 1990
[cited by applicant]
EP 1399483B1
· 2010
[cited by applicant]
EP 1689782B1
· 2010
[cited by applicant]
EP 2235059A1
· 2010
[cited by applicant]
EP 1959014B1
· 2011
[cited by applicant]
EP 2230254B1
· 2013
[cited by applicant]
EP 2681239B1
· 2015
[cited by applicant]
EP 2032989B2
· 2015
[cited by applicant]
EP 2681240B1
· 2017
[cited by applicant]
EP 2194067B1
· 2017
[cited by applicant]
EP 2863947B1
· 2018
[cited by applicant]
EP 2714733B1
· 2019
[cited by applicant]
EP 1469879B1
· 2019
[cited by applicant]
EP 2970433B1
· 2019
[cited by applicant]
EP 2814500B1
· 2020
[cited by applicant]
EP 2322550B1
· 2020
[cited by applicant]
EP 3458101B1
· 2020
[cited by applicant]
JP 2005533493A
· 2005
[cited by applicant]
JP 2010513278A
· 2010
[cited by applicant]
JP 2016528166A
· 2016
[cited by applicant]
JP 2016528168A
· 2016
[cited by applicant]
JP 2020518674A
· 2020
[cited by applicant]
KR 20210094669A
· 2021
[cited by applicant]
TW 202228775A
· 2022
[cited by applicant]
TW 202229350A
· 2022
[cited by applicant]
WO 8801649A1
· 1988
[cited by applicant]
WO 9311161A1
· 1993
[cited by applicant]
WO 9404678A1
· 1994
[cited by applicant]
WO 9425591A1
· 1994
[cited by applicant]
WO 03100008A2
· 2003
[cited by applicant]
WO 03106621A2
· 2003
[cited by applicant]
WO 2006060419A2
· 2006
[cited by applicant]
WO 2007062037A2
· 2007
[cited by applicant]
WO 2008005469A2
· 2008
[cited by applicant]
WO 2008076278A2
· 2008
[cited by applicant]
WO 2008079849A2
· 2008
[cited by applicant]
WO 2011028811A2
· 2011
[cited by applicant]
WO 2011161119A1
· 2011
[cited by applicant]
WO 2014177459A2
· 2014
[cited by applicant]
WO 2016064716A1
· 2016
[cited by applicant]
WO 2017011773A2
· 2017
[cited by applicant]
WO 2019084026A1
· 2019
[cited by applicant]
WO 2019084030A1
· 2019
[cited by applicant]
WO 2019173352A1
· 2019
[cited by applicant]
WO 2019183523A1
· 2019
[cited by applicant]
WO 2020006486A1
· 2020
[cited by applicant]
WO 2020132091A2
· 2020
[cited by applicant]
WO 2021041773A1
· 2021
[cited by applicant]
WO 2021243014A1
· 2021
[cited by applicant]
WO 2022081799A1
· 2022
[cited by applicant]
WO 2022081804A1
· 2022
[cited by applicant]
WO 2022187510A1
· 2022
[cited by applicant]
WO 2023001917A1
· 2023
[cited by applicant]
WO 2023019171A1
· 2023
[cited by applicant]
WO 2023122714A2
· 2023
[cited by applicant]
WO 2023133485A2
· 2023
[cited by applicant]
WO 2023133486A2
· 2023
[cited by applicant]
WO 2023133561A1
· 2023
[cited by applicant]
WO 2025014774A1
· 2025
[cited by examiner]
Kamboj et al (Front Ophthalmol (Lausanne) Dec. 12, 2023:3:1295902).
[cited by examiner]
NCT06384547 (Viridian; clinicaltrials.gov; pp. 1-8; May 23, 2024).
[cited by examiner]
NCT06021054 (Viridian; clinicaltrials.gov; pp. 1-9; Nov. 14, 2023).
[cited by examiner]
NCT05176639 (Viridian; clinicaltrials.gov; pp. 1-12; Dec. 3, 2021).
[cited by examiner]
Kamboj et al (Front. Ophthalmol. 3:1295902 (Dec. 12, 2023)).
[cited by examiner]
U.S. Appl. No. 19/242,715, Bedian; Vahe.
[cited by examiner]
U.S. Appl. No. 19/242,725, Bedian; Vahe.
[cited by examiner]
Final Office Action for U.S. Appl. No. 17/450,872 dated Sep. 19, 2023 (10 pages).
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2022/074764 dated Feb. 22, 2024 (8 pages).
[cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2021/054907 dated Apr. 27, 2023 (10 pages).
[cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2021/054914 dated Apr. 27, 2023 (8 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2021/054907 dated Feb. 23, 2022 (14 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2021/054914 dated Feb. 23, 2022 (13 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/074764 dated Nov. 4, 2022 (11 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/082214 dated Jul. 3, 2023 (12 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2023/060206 dated Jun. 21, 2023 (10 pages).
[cited by applicant]
International Search Report and Written Opinon for PCT/US2023/060207 dated Jun. 30, 2023 (10 pages).
[cited by applicant]
International Search Report for PCT/US2024/036800 dated Jan. 16, 2025 (7 pages).
[cited by applicant]
International Search Report for PCT/US2024/036803 dated Jan. 16, 2025 (8 pages).
[cited by applicant]
International Search Report for PCT/US2024/045630 dated Jan. 27, 2025 (5 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/450,872 dated Jan. 26, 2023 (10 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/501,362 dated Nov. 7, 2022 (18 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,639 dated Aug. 19, 2022 (9 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/818,798 dated Jun. 27, 2023 (14 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/822,978 dated Nov. 4, 2022 (19 pages).
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/822,978 dated Nov. 30, 2022 (13 pages).
[cited by applicant]
“A Study Evaluating Tepezza® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease”, ClinicalTrials.gov, U.S. National Library of Medicine, Oct. 12, 2020, NCT04583735, (9 pages).
[cited by applicant]
“Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopahty (IGF1RAbsGO)”, ClinicalTrials.gov, U.S. National Library of Medicine, Apr. 13, 2018, NCT03498417, (7 pages).
[cited by applicant]
“Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)”, ClinicalTrials.gov, U.S. National Library of Medicine, Aug. 1, 2019, NCT04040894, (7 pages).
[cited by applicant]
“Teprotumumab (RV 001) Treatment in Patient with Active Thyroid Eye Disease”, Clinicaltrials.gov, U.S. National Library of Medicine, Jun. 5, 2013, NCT01868997 (9 pages).
[cited by applicant]
“Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)”, ClinicalTrials.gov, U.S. National Library of Medicine…
[cited by applicant]
“Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)”, ClinicalTrials.gov, U.S. National Library of Medicine, Mar. 9, 2018, NCT03461211, (…
[cited by applicant]
Allen, Richard C., et al., “A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease”, American Academy of Ophthalmology, vol. 128, No. 8, Aug. 2021, pp. 1125-1128, DOI:10.1016/j.ophtha.2021…
[cited by applicant]
Baert, Filip , et al., “Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease”, The New England Journal of Medicine, vol. 348, 2003, pp. 601-608, DOI: 10.1056/NEJMoa020888, (8 pages).
[cited by applicant]
Beniaminovitz, Ainat , et al., “Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody”, The New England Journal of Medicine, vol. 342, 2000, pp. 613-619,…
[cited by applicant]
Chen, Hong , et al., “Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes”, Journal of Clinical Endocrinology and Metabolism, vol. 99, No. 9, Sep. 1, 2014, pp. E1635-E1640, D…
[cited by applicant]
Chiou, Carolina A., et al., “Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases”, American Journal of Ophthalmology Case Reports, vol. 22, Jun. 2021, 101075…
[cited by applicant]
Chothia, Cyrus , et al., “Canonical structures for the hypervariable regions of immunoglobulins”, Journal of Molecular Biology, vol. 196, No. 4, Aug. 20, 1987, pp. 901-917, DOI: 10.1016/0022-2836(87)90412-8, (18 pages).
[cited by applicant]
Chothia, Cyrus , et al., “Conformations of immunoglobulin hypervariable regions”, Nature, vol. 342, Dec. 1989, pp. 877-883, DOI: 10.1038/342877a0, (7 pages).
[cited by applicant]
Dall'Acqua, William F., et al., “Properties of human IgG1 s engineered for enhanced binding to the neonatal Fe receptor (FcRn)”, Journal of Biological Chemistry, vol. 281, No. 33, Jun. 21, 2006 (pp. 23514-23524).
[cited by applicant]
Diniz, Stefania B., et al., “Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population”, Ophthalmic Plastic and Reconstructive Surgery, vol. 37, No. 6, 2021, pp. 583-591, DO…
[cited by applicant]
Dolgin, Elie , “IGF-1R drugs travel from cancer cradle to Graves'”, Nature Biotechnology, vol. 38, 2020, pp. 385-388, DOI: 10.1038/s41587-020-0481-8, (4 pages).
[cited by applicant]
Dosiou, Chrysoula , et al., “Thyroid Eye Disease: Navigating the New Treatment Landscape”, Journal of the Endocrine Society, vol. 5, No. 5, 2021, Author Manuscript (40 pages).
[cited by applicant]
Douglas, Raymond S., et al., “Aberrant Expression of the Insulin-Like Growth Factor-Receptor by T Cells from Patients with Graves' Disease May Carry Functional Consequences for Disease Pathogenesis”, The Journal of Immu…
[cited by applicant]
Douglas, Raymond S., et al., “B Cells from Patients with Graves' Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis”, The Journal of Immunology, vol. 181, No. 8, 2008, pp. 5768-5774, DO…
[cited by applicant]
Douglas, Raymond S., et al., “Teprotumumab for the Treatment of Active Thyroid Eye Disease”, The New England Journal of Medicine, vol. 382, No. 4, 2020, pp. 341-352, DOI: 10.1056/NEJMoa1910434, (12 pages).
[cited by applicant]
Douglas, Raymond S., “Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis”, Eye, vol. 33, 2019, pp. 183-190, DOI: 10.1038/s414…
[cited by applicant]
Edmunds, Matthew Ross, “Investigation of Candidate Biomarkers in Graves' Disease and Thyroid-Associated Ophthalmopathy”, University of Birmingham, 2016, (306 pages).
[cited by applicant]
Ghosh, Subrata , et al., “Natalizumab for Active Crohn's Disease”, The New England Journal of Medicine, vol. 348, No. 1, Jan. 2, 2003, pp. 24-32, DOI: 10.1056/NEJMoa020732, (9 pages).
[cited by applicant]
Gualberto A., et al., “Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions”, Oncogene, vol. 28, No. 34, 2009, pp. 3009-3021, DOI:10.1038/onc.20…
[cited by applicant]
Herold, Kevan C., et al., “Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus”, The New England Journal of Medicine, vol. 346, No. 22, May 30, 2002, pp. 1692-1698, DOI: 10.1056/NEJMoa012864, (7 pages).
[cited by applicant]
Hoa, Neil , et al., “Nuclear Targeting of IGF-1 Receptor in Orbital Fibroblasts from Graves' Disease: Apparent Role of ADAM17”, PLoS One, vol. 7, No. 4, Apr. 2012, e34173, DOI: 10.1371/journal.pone.0034173, (9 pages).
[cited by applicant]
Holliger, Philipp , et al., ““Diabodies”: small bivalent and bispecific antibody fragments”, Proceedings of the National Academy of Sciences, vol. 90, No. 14, 1993, pp. 6444-6448, (5 pages).
[cited by applicant]
Holliger, Philipp , et al., “Engineered antibody fragments and the rise of single domains”, Nature Biotechnology, vol. 23, No. 9, 2005, pp. 1126-1136, DOI: 10.1038/nbt1142, (12 pages).
[cited by applicant]
Jain, Amy Patel, “Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease”, British Journal of Ophthalmology, vol. 106, No. 2, 2020, pp. 1-7, DOI: 10.1136/bjophthalmol-2020-317806, (7 pages…
[cited by applicant]
Janssen, Joseph A.M.J.L., et al., “Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy”, Cell, vol. 10, No. 2, 2021, 383, DOI: 10.3390/cells10020383, (17 pages).
[cited by applicant]
Kabat, Elvin A., et al., “Unusual distributions of amino acids in complementarity determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-com…
[cited by applicant]
Kahaly, George J, “Management of Graves Thyroidal and Extrathyroidal Disease: An Update”, The Journal of Clinical Endocrinology & Metabolism, vol. 105, No. 12, Dec. 2020, pp. 3704-3720, DOI: 10.1210/clinem/dgaa646, (17 …
[cited by applicant]
Keenan, Gregory F., et al., “A First-in-Human Phase 1 Randomized, Single-Ascending Dose Study of Lonigutamab, an Anit-IGF-1R Monoclonal Antibody, in Healthy Volunteers”, Poster Presentation, 49th North American Neuro-Op…
[cited by applicant]
Krieger, Christine C., et al., “Bidirectional TSH and IGF-1 Receptor Cross Talk Mediates Stimulation of Hyaluronan Secretion by Graves' Disease Immunoglobins”, The Journal of Clinical Endocrinology & Metabolism, vol. 10…
[cited by applicant]
Krieger, Christine C., et al., “Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?”, International Journal of Molecular Sciences, vol. 21, No. 18, 2020, 6561, DOI: 10.3390/ijms21186561, (13…
[cited by applicant]
Krieger, Christine C., et al., “Thyrotropin/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis”, The Journal of Clinical Endocrinology & Metabolism, vol. 101, No. 6, Jun. 1, 2016, pp. 2340-2347, DOI: 10.12…
[cited by applicant]
Kumar, Seema , et al., “A Stimulatory Thyrotropin Receptor Antibody Enhances Hyaluronic Acid Synthesis in Graves' Orbital Fibroblasts: Inhibition by an IGF-I Receptor Blocking Antibody”, The Journal of Clinical Endocrin…
[cited by applicant]
Lanzolla, G. , et al., “Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study”, Journal of Endocrinological Investigation, vol. 43, No.…
[cited by applicant]
Lathe, R. , “Synthetic oligonucleotide probes deduced from amino acid sequence data: Theoretical and practical considerations”, Journal of Molecular Biology, vol. 183, No. 1, May 5, 1985, pp. 1-12, DOI: 10.1016/0022-283…
[cited by applicant]
Lipsky, Peter E., “Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis”, The New England Journal of Medicine, vol. 343, No. 22, 2000, pp. 1594-1602, DOI: 10.1056/NEJM200011303432202, (9 pages).
[cited by applicant]
Liu, Alvin Y., et al., “Chimeric mouse-human lgG1 antibody that can mediate lysis of cancer cells”, Proceedings of the National Academy of Sciences, vol. 84, No. 10. May 15, 1987, pp. 3439-3443, DOI: 10.1073/pnas.84.10.…
[cited by applicant]
Liu, Alvin Y., et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity”, The Journal of Immunology, vol. 139, No. 10, Nov. 15, 1987, pp. 3521-3526, DOI: 10.40…
[cited by applicant]
Liu, Clarence , et al., “Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves”, Journal of Neurology, Neurosurgery…
[cited by applicant]
Ludgate, Marian , “Fibrosis in dysthyroid eye disease”, Eye, vol. 34, No. 2, Dec. 16, 2019 (pp. 279-284).
[cited by applicant]
Marinò, M. , et al., “Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy”, Journal of Endocrinological Investigation, vol. 42, 2019, pp. 471-480, DOI: …
[cited by applicant]
Markham, Anthony , “Teprotumumab: First Approval”, Drugs, vol. 80, No. 5, 2020, pp. 509-512, DOI: 10.1007/s40265-020-01287-y, (4 pages).
[cited by applicant]
Marks, James D., et al., “By-passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage”, Journal of Molecular Biology, vol. 222, 1991, pp. 581-597 (17 pages).
[cited by applicant]
Milgrom, Henry , et al., “Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody”, The New England Journal of Medicine, vol. 341, 1999, pp. 1966-1973, DOI: 10.1056/NEJM199912233412603, (8 pages).
[cited by applicant]
Morgan, Sarah L., et al., “Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes”, Thyroid, vol. 26, No. 12, 2016, DOI: 10…
[cited by applicant]
Morrison, Sherie L., et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proceedings of the National Academy of Sciences USA, Immunology, vol. 81, Nov. 1984, pp…
[cited by applicant]
Mueller, John P., et al., “Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells”, Molecular Immunology, vol. 34, No. 6, …
[cited by applicant]
Muyldermans, Serge , et al., “Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains”, Trends in Biochemical Sciences, vol. 26, No. 4, Apr. 1, 2001, pp. 230-235, DOI: 10.10…
[cited by applicant]
Neumann, Susanne , et al., “Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease”, European Thyroid Journal, vol. 9, No. 1,Nov. 2, 2020, pp. 59-65, DOI: 10.1159/000511538, (7 pages).
[cited by applicant]
Osher, Eliot , et al., “Therapeutic Targeting of the IGF Axis”, Cells, vol. 8, No. 8, 2019, 895, DOI: 10.3390/cells8080895, (25 pages).
[cited by applicant]
Ozzello, Daniel J., et al., “Early experience with teprotumumab for chronic thyroid eye disease”, American Journal of Ophthalmology Case Reports, vol. 19, 2020, 100744, DOI: 10.1016/j.ajoc.2020.100744, (3 pages).
[cited by applicant]
Patel, Amy , et al., “A New Era in the Treatment of Thyroid Eye Disease”, American Journal of Ophthalmology, vol. 208, Aug. 1, 2019 (pp. 281-288).
[cited by applicant]
Place, Robert F., et al., “Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro”, British Journal of Pharmacology, vol. 174, No.…
[cited by applicant]
Plückthun, A. , “Antibodies from
[cited by applicant]
Portielje, Johanna E., et al., “IL-12: a promising adjuvant for cancer vaccination”, Cancer Immunology, Immunotherapy, vol. 52, 2003, pp. 133-144, DOI: 10.1007/s00262-002-0356-5, (12 pages).
[cited by applicant]
Presta, Leonard G., “Selection, design, and engineering of therapeutic antibodies”, Journal of Allergy and Clinical Immunology, vol. 116, No. 4, Oct. 2005, pp. 731-736, DOI: 10.1016/j.jaci.2005.08.003, (6 pages).
[cited by applicant]
Pritchard, Jane , et al., “Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves' Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway”, The Jou…
[cited by applicant]
Riechmann, Lutz , et al., “Reshaping human antibodies for therapy”, Nature, vol. 332, 1988, pp. 323-327, DOI: 10.1038/332323a0 (5 pages).
[cited by applicant]
Riechmann, Lutz , et al., “Single domain antibodies: comparison of camel VH and camelised human VH domains”, Journal of Immunological Methods, vol. 231, No. 1-2, Dec. 10, 1999, pp. 25-38, DOI: 10.1016/S0022-1759(99)0013…
[cited by applicant]
Robbie, Gabriel J., et al., “A Novel Investigational Fe-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults”, Antimicrobial Agents and Chemotherapy, vol. 57, No. 12, Sep.…
[cited by applicant]
Safo, Myra B., et al., “A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease”, American Journal of Ophthalmology Case Reports, vol. 22, Jun. 2021, 101069, DOI: 10.1016/j.ajoc.2021.…
[cited by applicant]
Salvi, M. , et al., “Medical Treatment of Graves' Orbitopathy”, Hormone and Metabolic Research, vol. 47, No. 10, 2015, pp. 779-788, DOI: 10.1055/s-0035-1554721, (10 pages).
[cited by applicant]
Salvi, Mario , “Immunotherapy for Graves' ophthalmopathy”, Current Opinion in Endocrinology & Diabetes and Obesity, vol. 21, No. 5, Oct. 2014, pp. 409-414, DOI: 10.1097/MED.0000000000000097, Abstract (1 page).
[cited by applicant]
Slamon, Dennis J., et al., “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2”, The New England Journal of Medicine, vol. 344, No. 11, Mar. 15, 2001, pp. 78…
[cited by applicant]
Slentz, Dane H., et al., “Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy”, Expert Opinion on Investigational Drugs, vol. 29, No. 7, pp. 645-649, DOI: 10.1080/13543784.2020.17…
[cited by applicant]
Smith, Terry J., et al., “Immunoglobulins from Patients with Graves' Disease Induce Hyaluronan Synthesis in Their Orbital Fibroblasts through the Self-Antigen, Insulin-Like Growth Factor-I Receptor”, The Journal of Clin…
[cited by applicant]
Smith, Terry J., “Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy”, Frontiers in Endocrinology, vol. 11, 2020, DOI: 10.3389/fendo.2020.610337, (10 pages).
[cited by applicant]
Smith, Terry J., et al., “Teprotumumab for Thyroid-Associated Ophthalmopathy”, The New England Journal of Medicine, vol. 376, N. 18, 2017, pp. 1748-1761, DOI: 10.1056/NEJMoa1614949, (14 pages).
[cited by applicant]
Storz, Ulrich “Intellectual property protection”, mAbs, vol. 3, No. 3, 2011, pp. 310-317, DOI: 10.4161/mabs.3.3.15530, (9 pages).
[cited by applicant]
Taylor, Peter N., et al., “New insights into the pathogenesis and nonsurgical management of Graves orbitopathy”, Nature Reviews Endocrinology, vol. 16, No. 2, 2020, pp. 104-116, DOI: 10.1038/s41574-019-0305-4, (13 pages…
[cited by applicant]
Tsui, Shanli , et al., “Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves' Disease”, The Journal of Immunology, vol. …
[cited by applicant]
Tsurushita, Naoya , et al., “Humanization of a chicken anti-IL-12 monoclonal antibody”, Journal of Immunological Methods, vol. 295, No. 1-2, Dec. 2004, pp. 9-19, DOI: 10.1016/j.jim.2004.08.018, (11 pages).
[cited by applicant]
Ugradar, Shoaib , et al., “A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.”, Journal of neuro-ophthalmology: the official journal of the North American N…
[cited by applicant]
Ugradar, Shoaib , et al., “Improvement of asymmetric thyroid eye disease with teprotumumab”, British Journal of Ophthalmology, 2021, DOI: 10.1136/bjophthalmol-2020-318314, (5 pages).
[cited by applicant]
Ugradar, Shoaib , et al., “Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression”, Eye, vol. 35, No. 9, 2021, pp. 2607-2612, DOI: 10.1038/s41433-020-01297-w, (6 pages).
[cited by applicant]
Ugradar, Shoaib , et al., “Teprotumumab for the treatment of chronic thyroid eye disease”, Eye (London, England), vol. 36, No. 8, Aug. 2022, pp. 1553-1559, DOI:10.1038/s41433-021-01593-z (7 pages).
[cited by applicant]
Weightman, David R., et al., “Autoantibodies to Igf-1 Binding Sites in Thyroid Associated Ophthalmopathy”, Autoimmunity, vol. 16, No. 4, 1993, pp. 251-257, DOI: 10.3109/08916939309014643, (7 pages).
[cited by applicant]
Xin, Yan , et al., “Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease”, Clinical Pharmacokinetics, vol. 60, 2021, pp.…
[cited by applicant]
Yang, James C., et al., “A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer”, The New England Journal of Medicine, vol. 349, No. 5, Jul. 31, 2003, pp. 427…
[cited by applicant]
Yu, Run , “Thyroid function suppression after initiation of teprotumumab treatment”, Endocrine, vol. 73, No. 3, 2021, pp. 561-562, DOI: 10.1007/s12020-021-02676-3, (2 pages).
[cited by applicant]
International Search Report for PCT/US2024/060579 dated Apr. 3, 2025 (6 pages).
[cited by applicant]
International Search Report for PCT/US2025/010700 dated Apr. 24, 2025 (5 pages).
[cited by applicant]
Partial Search Report for PCT/US2024/036800 dated Oct. 21, 2024 (13 pages).
[cited by applicant]
Partial Search Report for PCT/US2024/036803 dated Oct. 21, 2024 (30 pages).
[cited by applicant]
Partial Search Report for PCT/US2025/010706 dated May 13, 2025 (11 pages).
[cited by applicant]
Partial Search Report for PCT/US2025/010718 dated May 12, 2025 (34 pages).
[cited by applicant]
“International Nonproprietary Names for Pharmaceutical Substances (INN)”, WHO Drug Information, vol. 22, No. 4, Jan. 1, 2008 URL: https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl…
[cited by applicant]
Cui, Xuejiao, et al., “A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves; orbitopathy”, Frontiers in Immunology, vol. 19, Jan. 19, 2023 (12 pages).
[cited by applicant]
Foster, Kelly, et al., “6461 VRDN-003, A Full Antagonist Antibody To The IGF-1 Receptor For Thyroid Eye Disease (TED): Safety And Pharmacokinetic Results Of Subcutaneous Administration In Healthy Volunteers”, Abstract, …
[cited by applicant]
Foster, Kelly, et al., “Thyroid FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED”, …
[cited by applicant]
International Search Report for PCT Application No. PCT/US2025/010718 dated Jul. 3, 2025 (14 pages).
[cited by applicant]
International Search Report for PCT/US2025/010706 dated Jul. 17, 2025 (7 pages).
[cited by applicant]
Zeng, Xianke, et al., “Sequencing of Type I IGF Receptor (IGF1R) Inhibition Affects Chemotherapy Response In Vitro and In Vivo”, Clinical Cancer Research, Author Manuscript, vol. 15, No. 8, 2009, pp. 2840-2849, DOI:10.1…
[cited by applicant]
Bartalena, Luigi , et al., “The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy”, European Thyroid Journal, vol. 5, No. 1, 2016, pp. 9-26, DOI…
[cited by applicant]
Chang, Shu-Hong , et al., “Novel ways to attack inflammation in thyroid eye disease”, Expert Review of Ophthalmology, vol. 5, No. 3, 2010, pp. 277-281, DOI: 10.1586/eop. 10.35 (6 pages).
[cited by applicant]
Cockerham, Kimberly P., et al., “Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States”, Ophthalmology and Therapy, vol. 10, No. 4, 2021, pp. 975-987, DOI:10.1007/s40123-021-00385-8 (13 pages…
[cited by applicant]
Douglas, Raymond S., et al., “Increased Generation of Fibrocytes in Thyroid-Associated Ophthalmopathy”, The Journal of Clinical Endocrinology and Metabolism, vol. 95, No. 1, Jan. 2010, pp. 430-438, DOI:10.1210/jc.2009-1…
[cited by applicant]
Gould, Daniel J., et al., “The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy”, Aesthetic Plastic Surgery, vol. 36, No. 3, 2012, pp. 638-648, DOI:10.1007/s00266-011-9843-4 (11 pages).
[cited by applicant]
Kim , et al., “Is modified clinical activity score an accurate indicator of diplopia progression in Graves' orbitopathy patients?”, Endocrine Journal, vol. 63, No. 12, Dec. 30, 2016, pp. 1133-1140, DOI:10.1507/endocrj. …
[cited by applicant]
Mohyi, Michelle , et al., “IGF1 receptor and thyroid-associated ophthalmopathy”, Journal of Molecular Endocrinology, Author Manuscript, vol. 61, No. 1, 2018, pp. T29-T43, DOI:10.1530/JME-17-0276 (26 pages).
[cited by applicant]
Naik, Vibhavari M., et al., “Immunopathogenesis of thyroid eye disease: emerging paradigms”, Survey of Ophthalmology, vol. 55, No. 3, 2010, pp. 215-226, DOI:10.1016/j.survophthal.2009.06.009 (20 pages).
[cited by applicant]
Piantanida, E. , et al., “Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?”, Journal of Endocrinological Investigation, vol. 40, No. 8, Jun. 20, 2017, pp. 885-887, DOI:…
[cited by applicant]
Smith, Terry J., “Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?”, Pharmacological Reviews, vol. 62, No. 2, 2010, pp. 199-236, DOI:10.1124/pr.109.00246…
[cited by applicant]
Smith, Terry J., “Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathy”, Expert Review of Ophthalmology, vol. 11, No. 2, 2016,…
[cited by applicant]
Strianese, Diego , “Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease”, Current Opinion in Ophthalmology, vol. 28, No. 5, Sep. 28, 2017, pp. 505-513, DOI:10.1097/ICU.000000…
[cited by applicant]
Uddin, Jimmy M., et al., “Phenotypes of Thyroid Eye Disease”, Ophthalmic plastic and reconstructive surgery, vol. 34, No. 4S Suppl 1, 2018, pp. S28-S33, DOI:10.1097/IOP.0000000000001147 (6 pages).
[cited by applicant]
Ugradar, Shoaib , et al., “Noninflammatory Thyroid Eye Disease”, Ophthalmic Plastic and Reconstructive Surgery, vol. 35, No. 5, 2019, pp. 461-464, DOI:10.1097/IOP.0000000000001087 (4 pages).
[cited by applicant]
Wang, Yao , et al., “Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.”, Therapeutics and Clinical Risk Management, vol. 15, pp. 1305-1318, Nov. 11, 2019, DOI:10.2147/TCRM.S193018 (15 pages).
[cited by applicant]
Weiler, Danielle L., “Thyroid eye disease: a review”, Clinical & Experimental Optometry, vol. 100, No. 1, 2017, pp. 20-25, DOI:10.1111/cxo. 12472 (6 pages).
[cited by applicant]
Xu, Nuo , et al., “Ocular surface characteristics and impression cytology in patients with active versus inactive Thyroid Eye Disease”, Eye Science, vol. 27, No. 2, 2012, pp. 64-68, DOI:10.3969/j.issn. 1000-4432.2012.02…
[cited by applicant]